Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DAVITA INC.DVA · Entity 3482 | Director | August 15, 2026 | August 18, 2026 |
| LABCORP HOLDINGS INC.LH · Entity 1277 | Director · President & CEO | August 11, 2026 | August 12, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | EVP & Pres-Global Human Health | November 01, 2018 | November 02, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DAVITA INC.
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,970 |
Reported balance
After 2026-08-15 transaction · row 1
1 source rowRow 1 · 2026-08-15 · Grant · Acquired 278 · Balance 5,970 |
LABCORP HOLDINGS INC.
Report date August 11, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,565 |
Reported balance
After 2026-08-11 transaction · row 1
1 source rowRow 1 · 2026-08-11 · Sale · Disposed 4,669 · Balance 102,565 F1: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
Merck & Co., Inc.
Report date November 01, 2018 · Filed November 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-11-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2018-11-01 · Exercise / conversion · Acquired 277,879 · Balance 277,879 Row 2 · 2018-11-01 · Sale · Disposed 132,744 · Balance 145,135 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.6800 to $73.3900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Row 3 · 2018-11-01 · Sale · Disposed 145,135 · Balance 0 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.4000 to $74.0200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.29 · Expires 2022-05-01 | Direct | 0 |
Reported balance
After 2018-11-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-11-01 · Exercise / conversion · Disposed 277,879 · Balance 0 F5: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 55,405.9747 |
Reported balance
Holding disclosure · report date 2018-11-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 55,405.9747 F4: Holdings include shares acquired in dividend reinvestment transactions. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.6800 to $73.3900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.4000 to $74.0200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F4: Holdings include shares acquired in dividend reinvestment transactions.
F5: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 02, 2020 Filed Nov 4, 2020 22:43 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 2,006 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-028188 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:07 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 1,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005615 · form4.xml · derivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,540 Underlying: Common Stock · 1,227 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 12, 2020. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 12, 2020. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:07 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 1,227 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005615 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:37 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 45,600 | $0.00 Strike: $182.51 | $0.00 |
DisclosureSEC source: 0001127602-20-003954 · form4.xml · derivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,600 Underlying: Common Stock · 45,600 shares Expires 2030-02-03 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:37 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 10,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003954 · form4.xml · derivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,767 Underlying: Common Stock · 10,520 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| November 01, 2019 Filed Nov 6, 2019 01:04 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 65,100 | $0.00 Strike: $191.51 | $0.00 |
DisclosureSEC source: 0001127602-19-031969 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,100 Underlying: Common Stock · 65,100 shares Expires 2029-10-31 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| November 01, 2019 Filed Nov 6, 2019 01:04 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 24,800 | $0.00 Strike: $166.53 | $0.00 |
DisclosureSEC source: 0001127602-19-031969 · form4.xml · derivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,800 Underlying: Common Stock · 24,800 shares Expires 2029-10-31 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal installments beginning on the date reflected in this column. Read SEC document |
| November 01, 2019 Filed Nov 6, 2019 01:04 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 6,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031969 · form4.xml · derivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,247 Underlying: Common Stock · 6,020 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on 11/1/2020. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on 11/1/2020. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:24 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 1,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-005999 · form4.xml · derivative · entry 4 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,227 Underlying: Common Stock · 1,227 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest fully on February 12, 2020. F3 · derivative.expiration_date: The Restricted Stock Units vest fully on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:24 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 1,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-005999 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,038 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 12, 2019. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 12, 2019. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:24 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 1,038 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-005999 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| November 19, 2018 Filed Feb 14, 2019 21:24 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GiftCommon Stock | 610 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-005999 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,424 Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 20:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 277,879 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-18-015139 · doc4.xml · derivative · entry 5 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 277,879 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 20:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 145,135 | $73.66 | $10,691,181.10 |
DisclosureSEC source: 0001225208-18-015139 · doc4.xml · nonDerivative · entry 3 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.4000 to $74.0200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 20:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 132,744 | $73.98 | $9,819,763.95 |
DisclosureSEC source: 0001225208-18-015139 · doc4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,135 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.6800 to $73.3900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 20:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 277,879 | $39.29 | $10,917,865.91 |
DisclosureSEC source: 0001225208-18-015139 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:49 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-18-013520 · doc4.xml · derivative · entry 4 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2012, 5/4/2013 and 5/4/2014. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:49 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 7,360 | $70.18 | $516,510.82 |
DisclosureSEC source: 0001225208-18-013520 · doc4.xml · nonDerivative · entry 3 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 55,405.9747 F3 · kind: The sale reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.7300 to $70.4400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F5 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:49 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 100,000 | $70.18 | $7,017,780.00 |
DisclosureSEC source: 0001225208-18-013520 · doc4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.6600 to $70.4200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:49 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 100,000 | $36.56 | $3,656,000.00 |
DisclosureSEC source: 0001225208-18-013520 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 14:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-18-010754 · doc4.xml · derivative · entry 4 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2012, 5/4/2013 and 5/4/2014. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 14:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 34,094 | $61.00 | $2,079,785.14 |
DisclosureSEC source: 0001225208-18-010754 · doc4.xml · nonDerivative · entry 3 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 62,765.9747 F3 · kind: The sale reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.6100 to $61.3100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F5 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 14:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 100,000 | $61.00 | $6,100,160.00 |
DisclosureSEC source: 0001225208-18-010754 · doc4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.5900 to $61.3200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 14:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 100,000 | $36.56 | $3,656,000.00 |
DisclosureSEC source: 0001225208-18-010754 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 139,063 | $0.00 Strike: $57.75 | $0.00 |
DisclosureSEC source: 0001225208-18-008940 · doc4.xml · derivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,063 Underlying: Common Stock · 139,063 shares Expires 2028-05-03 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:32 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 34,094 | $54.72 | $1,865,623.68 |
DisclosureSEC source: 0001225208-18-005009 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,094 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/15. Performance shares were paid out at 138 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2017. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 14:14 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 1,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005650 · form4.xml · derivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038 Underlying: Common Stock · 1,038 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 12, 2019. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 20:56 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 1,263 | $169.29 | $213,813.27 |
DisclosureSEC source: 0001127602-18-004896 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,034 F2 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 20:56 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 1,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-004896 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,263 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested fully on February 7, 2018. F3 · derivative.expiration_date: The Restricted Stock Units vested fully on February 7, 2018. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 20:56 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 1,263 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-004896 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 50,994 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-18-001054 · doc4.xml · derivative · entry 4 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 50,994 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2012, 5/4/2013 and 5/4/2014. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 50,608 | $61.63 | $3,118,971.04 |
DisclosureSEC source: 0001225208-18-001054 · doc4.xml · nonDerivative · entry 3 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 62,765.9747 F2 · kind: The sale reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 50,994 | $61.63 | $3,142,760.22 |
DisclosureSEC source: 0001225208-18-001054 · doc4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 16, 2018 Filed Jan 16, 2018 22:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 50,994 | $36.56 | $1,864,340.64 |
DisclosureSEC source: 0001225208-18-001054 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 18:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | GiftCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-018771 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 113,373.9747 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 162,625 | $0.00 Strike: $63.97 | $0.00 |
DisclosureSEC source: 0001225208-17-009429 · doc4.xml · derivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,625 Underlying: Common Stock · 162,625 shares Expires 2027-05-04 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 22:36 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 53,850 | $63.48 | $3,418,166.45 |
DisclosureSEC source: 0001225208-17-007537 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 116,335.9747 F1 · kind: The sale reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.2600 to $63.6900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 39,970 | $65.85 | $2,632,024.50 |
DisclosureSEC source: 0001225208-17-005091 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,970 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/14. Performance shares were paid out at 158 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2016. Read SEC document |
| February 27, 2017 Filed Apr 10, 2017 19:21 UTC Amendment | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 37,758 | $65.85 | $2,486,364.30 |
DisclosureSEC source: 0001225208-17-007833 · doc4a.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,758 F1 · shares: The Amended Form 4 is being filed to correct an administrative error with regard to the number of shares withheld for payment of taxes on the 2/27/17 vesting of performance share units. The number of securities beneficially owned following the reported transaction should have been reported as 37,758.0000, and includes shares acquired in dividend reinvestment transactions. F1 · balance_after: The Amended Form 4 is being filed to correct an administrative error with regard to the number of shares withheld for payment of taxes on the 2/27/17 vesting of performance share units. The number of securities beneficially owned following the reported transaction should have been reported as 37,758.0000, and includes shares acquired in dividend reinvestment transactions. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 19:01 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 1,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-005295 · form4.xml · derivative · entry 2 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,263 Underlying: Common Stock · 1,560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 9, 2017. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 9, 2017. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 19:01 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 1,560 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-005295 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 19:20 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 1,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-004717 · form4.xml · derivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,823 Underlying: Common Stock · 1,263 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 7, 2018. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 20:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 26,135 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001225208-17-002444 · doc4.xml · derivative · entry 6 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,135 shares Expires 2020-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/7/2011, 5/7/2012 and 5/7/2013. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 20:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 10,200 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-17-002444 · doc4.xml · derivative · entry 5 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,994 Underlying: Common Stock · 10,200 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2012, 5/4/2013 and 5/4/2014. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 20:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 36,335 | $63.73 | $2,315,698.59 |
DisclosureSEC source: 0001225208-17-002444 · doc4.xml · nonDerivative · entry 3 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.3200 to $64.0300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 20:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 10,200 | $36.56 | $372,912.00 |
DisclosureSEC source: 0001225208-17-002444 · doc4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2017 Filed Feb 6, 2017 20:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 26,135 | $33.49 | $875,261.15 |
DisclosureSEC source: 0001225208-17-002444 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2016 Filed Sep 1, 2016 19:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 39,200 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001225208-16-038666 · doc4.xml · derivative · entry 4 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,135 Underlying: Common Stock · 39,200 shares Expires 2020-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/7/2011, 5/7/2012 and 5/7/2013. Read SEC document |
| September 01, 2016 Filed Sep 1, 2016 19:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 39,200 | $62.61 | $2,454,308.08 |
DisclosureSEC source: 0001225208-16-038666 · doc4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.4000 to $62.9800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| September 01, 2016 Filed Sep 1, 2016 19:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 39,200 | $33.49 | $1,312,808.00 |
DisclosureSEC source: 0001225208-16-038666 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.